UW research shows new prognosis tool for deadly brain cancer

June 20, 2012

Madison, Wis. -- A diagnosis of glioblastoma multiforme (GBM) is generally a death sentence, but new research from the University of Wisconsin-Madison lab of Dr. John Kuo shows that at least one subtype is associated with a longer life expectancy. This discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.

People diagnosed with GBM live on average less than 15 months after diagnosis, even after undergoing aggressive surgery, radiation and chemotherapy. But not all GBM cancers are the same, and Kuo's study outlines a new method for sub-typing GBM tumor lines by the proteins they express.

The paper, published early online by the journal Clinical Cancer Research, shows that people who have a subtype of GBM that expresses a particular protein, known for short as CNP, may have a less aggressive subtype of cancer. The survival rate for those with the subtype is sometimes measured in years, not months.

The group isolated tumor lines from five human patients and grew them in the lab, and then looked for biomarkers specific to each line. They later transplanted the tissue into the brains of mice with compromised immune systems.

The researchers also looked for the CNP subtype in samples from 115 human patients and then looked at data on survival rates for those patients. They found that some patients with the protein lived much longer, as long as 10 years after diagnosis.

"We found that this protein was correlated with a less invasive type of cancer in mice, and when we looked at samples of human tumors, remarkably, we also found that the less invasive tumors expressed the CNP protein,'' says Kuo, assistant professor of neurological surgery and human oncology at UW School of Medicine and Public Health.

Kuo says the sub-typing could lead to more accurate prognosis for patients with a GBM diagnosis. Currently, most sub-typing of GBM tumors is based on mRNA, which can be difficult to do. But Kuo says that most hospitals can run assays for proteins, making the test simpler and easier.

In addition, says Michael Zorniak, Kuo's graduate student and lead author on the paper, the new way of typing tumors could lead to designer chemotherapy for GBM.

"As we understand how tumors are differentiated, we can start devising personalized therapies that are targeted to the specific sub-type of cancer,'' he says. "This can help us gain leverage against this difficult cancer."

For example, researchers could create monoclonal antibodies that bind only to the CNP type of cancer, in the way that some subtypes of breast cancer are currently targeted.
-end-
The research will be published in the July issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, and is available on-line here: http://clincancerres.aacrjournals.org/content/early/2012/05/15/1078-0432.CCR-12-0339

The research was supported by grants from the National Institutes of Health (T32GM007507, UL1RR025011, RC4AA020476) the National Cancer Institute (HHSN261201000130C, P30CA014520) the Wisconsin Partnership Program, the Center for Stem Cell and Regenerative Medicine, the University of Wisconsin-Madison (Shapiro research scholarship, Graduate School, Department of Neurological Surgery), the HEADRUSH Brain Tumor Research Professorship and the Roger Loff Memorial Fund for GBM Research.

University of Wisconsin-Madison

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.